Targeting mGluR group III for the treatment of neurodegenerative diseases

被引：0

作者：

Rabeh, Nadia ^{[1
,2
,3
]}

Hajjar, Baraa ^{[1
]}

Maraka, Jude O. ^{[1
]}

Sammanasunathan, Ashwin F. ^{[1
]}

Khan, Mohammed ^{[1
]}

Alkhaaldi, Saif M. I. ^{[1
]}

Mansour, Samy ^{[1
]}

Almheiri, Rashed T. ^{[1
]}

Hamdan, Hamdan ^{[1
,4
]}

Abd-Elrahman, Khaled S. ^{[2
,3
,5
,6
,7
]}

机构：

[1] Khalifa Univ, Coll Med & Hlth Sci, Dept Physiol & Immunol, Abu Dhabi, U Arab Emirates

[2] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada

[3] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 1Z3, Canada

[4] Khalifa Univ Sci & Technol, Healthcare Engn Innovat Ctr HEIC, Abu Dhabi, U Arab Emirates

[5] Khalifa Univ, Coll Med & Hlth Sci, Dept Pharmacol & Therapeut, Abu Dhabi, U Arab Emirates

[6] Alexandria Univ, Fac Pharm, Dept Pharmacol & Toxicol, Alexandria 21521, Egypt

[7] Univ British Columbia, Fac Med, Dept Anesthesiol Pharmacol & Therapeut, 2176 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 168卷

关键词：

Glutamate; MGluR; GPCR; Neurodegeneration; Motor function; Cognitive function;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Glutamate, an excitatory neurotransmitter, is essential for neuronal function, and it acts on ionotropic or metabotropic glutamate receptors (mGluRs). A disturbance in glutamatergic signaling is a hallmark of many neurodegenerative diseases. Developing disease-modifying treatments for neurodegenerative diseases targeting glutamate receptors is a promising avenue. The understudied group III mGluR 4, 6-8 are commonly found in the presynaptic membrane, and their activation inhibits glutamate release. Thus, targeted mGluRs therapies could aid in treating neurodegenerative diseases. This review describes group III mGluRs and their pharmacological ligands in the context of amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's diseases. Attempts to evaluate the efficacy of these drugs in clinical trials are also discussed. Despite a growing list of group III mGluR-specific pharmacological ligands, research on the use of these drugs in neurodegenerative diseases is limited, except for Parkinson's disease. Future efforts should focus on delineating the contribution of group III mGluR to neurodegeneration and developing novel ligands with superior efficacy and a favorable side effect profile for the treatment of neurodegenerative diseases.

引用

页数：12

共 213 条

[1] Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease [J].

Abd-Elrahman, Khaled S. ;

Ferguson, Stephen S. G. .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2022, 62 :235-254

[2] D mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease [J].

Abd-Elrahman, Khaled S. ;

Hamilton, Alison ;

Hutchinson, Shaunessy R. ;

Liu, Fang ;

Russell, Ryan C. ;

Ferguson, Stephen S. G. .

SCIENCE SIGNALING, 2017, 10 (510)

[3] Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines [J].

Abe, Masahito ;

Seto, Mabel ;

Gogliotti, Rocco G. ;

Loch, Matthew T. ;

Bollinger, Katrina A. ;

Chang, Sichen ;

Engelberg, Eileen M. ;

Luscombe, Vincent B. ;

Harp, Joel M. ;

Bubser, Michael ;

Engers, Darren W. ;

Jones, Carrie K. ;

Rodricuez, Alice L. ;

Blobaum, Anna L. ;

Conn, P. Jeffrey ;

Niswender, Colleen M. ;

Lindsley, Craig W. .

ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10) :1110-1115

[4] Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: New tools to discriminate between metabotropic glutamate receptor subtypes [J].

Acher, FC ;

Tellier, FJ ;

Azerad, R ;

Brabet, IN ;

Fagni, L ;

Pin, JPR .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) :3119-3129

[5] (S)-Homo-AMPA, a specific agonist at the mGlu(6) subtype of metabotropic glutamic acid receptors [J].

Ahmadian, H ;

Nielsen, B ;

Brauner-Osborne, H ;

Johansen, TN ;

Stensbol, TB ;

Slok, FA ;

Sekiyama, N ;

Nakanishi, S ;

KrogsgaardLarsen, P ;

Madsen, U .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (22) :3700-3705

[6] EXPRESSION OF MESSENGER-RNAS OF L-AP4-SENSITIVE METABOTROPIC GLUTAMATE RECEPTORS (MGLUR4, MGLUR6, MGLUR7) IN THE RAT RETINA [J].

AKAZAWA, C ;

OHISHI, H ;

NAKAJIMA, Y ;

OKAMOTO, N ;

SHIGEMOTO, R ;

NAKANISHI, S ;

MIZUNO, N .

NEUROSCIENCE LETTERS, 1994, 171 (1-2) :52-54

[7]

Al-Chalabi A., 2017, Lateral Scler. Front Degener, V18, P471

[8] Gene discovery in amyotrophic lateral sclerosis: implications for clinical management [J].

Al-Chalabi, Ammar ;

van den Berg, Leonard H. ;

Veldink, Jan .

NATURE REVIEWS NEUROLOGY, 2017, 13 (02) :96-104

[9] The epidemiology of ALS: a conspiracy of genes, environment and time [J].

Al-Chalabi, Ammar ;

Hardiman, Orla .

NATURE REVIEWS NEUROLOGY, 2013, 9 (11) :617-628

[10] Synthesis and preliminary biological evaluation of (2S,1′R,2′S)-and (2S,1S,2′R)-2-(2′-phosphonocyclopropyl)glycines, two novel conformationally constrained L-AP4 analogues [J].

Amori, L ;

Serpi, M ;

Marinozzi, M ;

Costantino, G ;

Diaz, MG ;

Hermit, MB ;

Thomsen, C ;

Pellicciari, R .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) :196-199

← 1 2 3 4 5 6 7 8 9 10 →